S-9-(2,3-dihydroxypropyl)-adenine



Compound IDCDAMM02119
Common nameS-9-(2,3-dihydroxypropyl)-adenine
IUPAC name3-(6-aminopurin-9-yl)propane-1,2-diol
Molecular formulaC8H11N5O2

Experimental data

Retention time0.54
Adduct[M+H]+
Actual mz210.099
Theoretical mz210.098
Error3.45
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score5.3091

Identifiers and class information

Inchi keyGSLQFBVNOFBPRJ-RXMQYKEDSA-N
SmilesOCC(O)CN1C=NC=2C(=NC=NC21)N
SuperclassOrganoheterocyclic compounds
ClassImidazopyrimidines

Pharmacokinetic properties

Number of descriptor values(#stars)0
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)6
Number of reactive functional groups (#rtvFG)0
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)209.207
Computed dipole moment(dipole)5.13
Total solvent accessible surface area (SASA)417.262
Hydrophobic component of SASA (FOSA)92.343
Hydrophilic component of SASA (FISA)217.477
Pie component of the SASA (PISA)107.442
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)679.165
Number of hydrogen bond donors (donorHB)4
Number of hydrogen bond acceptors (accptHB)7.4
Free energy of solvation of dipole (dip^2/V)0.0387476
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0354694
Globularity descriptor (glob)0.895516
Predicted polarizability in cubic angstroms (QPpolrz)18.2
Predicted hexadecane/gas partition coefficient (QPlogPC16)7.764
Predicted octanol/gas partition coefficient (QPlogPoct)16.149
Predicted water/gas partition coefficient (QPlogPw)14.757
Predicted octanol/water partition coefficient (QPlogPo/w)-1.023
Predicted aqueous solubility (QPlogS)-1.432
Conformation-independent predicted aqueous solubility (CIQPlogS)-1.535
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-3.735
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)85.815
Predicted brain/blood partition coefficient (QPlogBB)-1.606
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)34.806
Predicted skin permeability, log Kp (QPlogKp)-4.573
PM3 calculated ionization potential (IP(ev))8.446
PM3 calculated electron affinity (EA(eV))0.202
Number of likely metabolic reactions (#metab)3
Prediction of binding to human serum albumin (QPlogKhsa)-0.845
Predicted qualitative human oral absorption (HumanOralAbsorption)2
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)55.561
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)111.671
Number of nitrogen and oxygen atoms (#NandO)7
Number of violations of Lipinski’s rule of five (RuleOfFive)0
Number of violations of Jorgensen’s rule of three (RuleOfThree)0

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P06241FYNTyrosine-protein kinase FYNT17980SEA
P29274ADORA2AAdenosine A2a receptorT77365SEA
P30542ADORA1Adenosine A1 receptorT92072SEA
P0DMS8ADORA3Adenosine A3 receptorT36059SEA
P29275ADORA2BAdenosine A2b receptorT86679SEA
Q02750MAP2K1Dual specificity mitogen-activated protein kinase kinase 1T99057SEA
P26358DNMT1DNA (cytosine-5)-methyltransferase 1 (by homology)T88304SEA
P00813ADAAdenosine deaminaseT03661SEA
P55263ADKAdenosine kinaseT91661SEA
P04406GAPDHGlyceraldehyde-3-phosphate dehydrogenase liverT39321SEA
P23526AHCYAdenosylhomocysteinaseT68698SEA
P08631HCKTyrosine-protein kinase HCKT31406SEA
Q8TEK3DOT1LHistone-lysine N-methyltransferase, H3 lysine-79 specificT87686SEA
Q9UBF8PI4KBPI4-kinase beta subunitT12541SEA
Q13233MAP3K1Mitogen-activated protein kinase kinase kinase 1T06031SEA
P47900P2RY1Purinergic receptor P2Y1T67818SEA
P41231P2RY2Purinergic receptor P2Y2T93515SEA
Q99873PRMT1Protein-arginine N-methyltransferase 1T16808SEA
Q96KQ7EHMT2Histone-lysine N-methyltransferase, H3 lysine-9 specific 3T53251SEA
P16885PLCG2Phospholipase C-gamma-2T93922SEA
P14625HSP90B1EndoplasminT81311SEA
Q9H9B1EHMT1Histone-lysine N-methyltransferase, H3 lysine-9 specific 5T39996SEA
Q9UBC3DNMT3BDNA (cytosine-5)-methyltransferase 3BT65501SEA
P51575P2RX1P2X purinoceptor 1T69091SEA
P17707AMD1S-adenosylmethionine decarboxylase 1T55922SEA
Q8WTS6SETD7Histone-lysine N-methyltransferase SETD7T73184SEA
Q9NVM4PRMT7Protein arginine N-methyltransferase 7T79501SEA
O43463SUV39H1Histone-lysine N-methyltransferase SUV39H1T39519SEA
Q92800EZH1Histone-lysine N-methyltransferase EZH1T17986SEA
P21860ERBB3Receptor tyrosine-protein kinase erbB-3T86350SEA
Q99571P2RX4P2X purinoceptor 4T60330SEA
Q13705ACVR2BActivin receptor type-2BT80338SEA
Q86Y97KMT5CHistone-lysine N-methyltransferase KMT5CT68490SEA
O95622ADCY5Adenylate cyclase type 5T19531SEA
Q9NZ70TAK1TGF-beta-activated kinase 1T04361SEA
Q15569TESK1Testis-specific kinase 1T49542SEA
P27037ACVR2AActivin receptor type IIAT47366SEA
Q9Y2K2SIK3SIK family kinase 3T81830SEA
Q8IWQ3BRSK2BR serine/threonine kinase 2T10375SEA
P57078RIPK4PKC-delta-interacting protein kinaseT93594SEA
Q9NY57STK32BYet another novel kinase 2T01255SEA
Q13873BMPR2Bone morphogenetic protein receptorT60213SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T17980DI0286Myeloproliferative neoplasm[ICD-11: 2A20]P06241FYN
T77365DI0319Orthostatic hypotension[ICD-11: BA21]P29274ADORA2A
T77365DI0331Parkinsonism[ICD-11: 8A00]P29274ADORA2A
T77365DI0359Radionuclide imaging[ICD-11: N.A.]P29274ADORA2A
T92072DI0319Orthostatic hypotension[ICD-11: BA21]P30542ADORA1
T36059DI0351Psoriasis[ICD-11: EA90]P0DMS8ADORA3
T36059DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P0DMS8ADORA3
T86679DI0180Herpes simplex infection[ICD-11: 1F00]P29275ADORA2B
T86679DI0397Supraventricular tachyarrhythmia[ICD-11: BC81]P29275ADORA2B
T99057DI0262Metastatic tumour[ICD-11: 2D50-2E2Z]Q02750MAP2K1
T99057DI0336Phakomatoses/hamartoneoplastic syndrome[ICD-11: LD2D]Q02750MAP2K1
T88304DI0012Acute myeloid leukaemia[ICD-11: 2A60]P26358DNMT1
T88304DI0284Myelodysplastic syndrome[ICD-11: 2A37]P26358DNMT1
T88304DI0286Myeloproliferative neoplasm[ICD-11: 2A20]P26358DNMT1
T03661DI0016Adaptive immunity immunodeficiency[ICD-11: 4A01]P00813ADA
T03661DI0245Malignant haematopoietic neoplasm[ICD-11: 2B33]P00813ADA
T03661DI0249Mature B-cell leukaemia[ICD-11: 2A82]P00813ADA
T91661DI0134Epilepsy/seizure[ICD-11: 8A61-8A6Z]P55263ADK
T39321DI0279Muscular atrophy[ICD-11: 8B61]P04406GAPDH
T39321DI0280Muscular dystrophy[ICD-11: 8C70]P04406GAPDH
T31406DI0207Indeterminate colitis[ICD-11: DD72]P08631HCK
T87686DI0012Acute myeloid leukaemia[ICD-11: 2A60]Q8TEK3DOT1L
T87686DI0245Malignant haematopoietic neoplasm[ICD-11: 2B33]Q8TEK3DOT1L
T87686DI0250Mature B-cell lymphoma[ICD-11: 2A85]Q8TEK3DOT1L
T12541DI0086Chronic obstructive pulmonary disease[ICD-11: CA22]Q9UBF8PI4KB
T12541DI0440Zoonotic viral diseaseICD-11: 1D6YQ9UBF8PI4KB
T93515DI0436Visual system disease[ICD-11: 9E1Z]P41231P2RY2
T16808DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]Q99873PRMT1
T53251DI0062Breast cancer[ICD-11: 2C60-2C6Y]Q96KQ7EHMT2
T53251DI0339Postoperative inflammation[ICD-11: 1A00-CA43]Q96KQ7EHMT2
T53251DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]Q96KQ7EHMT2
T81311DI0238Lung cancer[ICD-11: 2C25]P14625HSP90B1
T39996DI0062Breast cancer[ICD-11: 2C60-2C6Y]Q9H9B1EHMT1
T39996DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]Q9H9B1EHMT1
T65501DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]Q9UBC3DNMT3B
T55922DI0004Acidosis[ICD-11: 5C73]P17707AMD1
T73184DI0062Breast cancer[ICD-11: 2C60-2C6Y]Q8WTS6SETD7
T17986DI0012Acute myeloid leukaemia[ICD-11: 2A60]Q92800EZH1
T17986DI0238Lung cancer[ICD-11: 2C25]Q92800EZH1
T17986DI0245Malignant haematopoietic neoplasm[ICD-11: 2B33]Q92800EZH1
T17986DI0250Mature B-cell lymphoma[ICD-11: 2A85]Q92800EZH1
T17986DI0251Mature T-cell lymphoma[ICD-11: 2A90]Q92800EZH1
T17986DI0361Renal cell carcinoma[ICD-11: 2C90]Q92800EZH1
T17986DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]Q92800EZH1
T17986DI0423Ureteral cancer[ICD-11: 2C92]Q92800EZH1
T86350DI0062Breast cancer[ICD-11: 2C60-2C6Y]P21860ERBB3
T86350DI0095Colorectal cancer[ICD-11: 2B91]P21860ERBB3
T86350DI0172Head and neck cancer[ICD-11: 2D42]P21860ERBB3
T86350DI0238Lung cancer[ICD-11: 2C25]P21860ERBB3
T86350DI0246Malignant mesenchymal neoplasm[ICD-11: 2B5D-2B5Y]P21860ERBB3
T86350DI0259Metastatic lymph node neoplasm[ICD-11: 2D60]P21860ERBB3
T86350DI0326Pancreatic cancer[ICD-11: 2C10]P21860ERBB3
T86350DI0351Psoriasis[ICD-11: EA90]P21860ERBB3
T86350DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P21860ERBB3
T86350DI0393Squamous cell carcinoma[ICD-11: 2B60-2D01]P21860ERBB3
T80338DI0295Nervous system paraneoplastic/autoimmune disorder[ICD-11: 8E4A]Q13705ACVR2B
T04361DI0250Mature B-cell lymphoma[ICD-11: 2A85]Q9NZ70TAK1
T47366DI0012Acute myeloid leukaemia[ICD-11: 2A60]P27037ACVR2A
T47366DI0198Idiopathic inflammatory myopathy[ICD-11: 4A41]P27037ACVR2A
T81830DI0321Ovarian cancer[ICD-11: 2C73]Q9Y2K2SIK3
T60213DI0223Joint derangement[ICD-11: FA34]Q13873BMPR2
T60213DI0346Prostate cancer[ICD-11: 2C82]Q13873BMPR2
T60213DI0426Urinary system disease[ICD-11: GC2Z]Q13873BMPR2
T60213DI0428Urinary/pelvic organs injury[ICD-11: NB92]Q13873BMPR2

Copyright © 2025